VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0500
-0.0800 (-1.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.1300
Open4.1100
Bid4.07 x 2200
Ask4.20 x 1400
Day's Range4.0100 - 4.2500
52 Week Range2.7700 - 10.3500
Volume1,867,294
Avg. Volume2,879,401
Market Cap298.855M
Beta (3Y Monthly)4.00
PE Ratio (TTM)N/A
EPS (TTM)-1.39
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.64
Trade prices are not sourced from all markets
  • Business Wire9 days ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its common stock to four employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.21 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on December 3, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

  • Business Wire11 days ago

    Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting

    Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies

  • Business Wire11 days ago

    Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from an investigator sponsored trial, led by Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center (MSK), evaluating duvelisib in combination with romidepsin in patients with relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) at the American Society of Hematology (ASH) 2018 Annual Meeting, taking place December 1-4, 2018, in San Diego. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.

  • GlobeNewswire12 days ago

    New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
    Zacks16 days ago

    Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?

    Is (VSTM) Outperforming Other Medical Stocks This Year?

  • Business Wirelast month

    Verastem Oncology Reports Third Quarter 2018 Financial Results

    Quarter Highlighted by FDA Approval of COPIKTRA™ Capsules

  • Business Wirelast month

    Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma (PTCL), an aggressive type of non-Hodgkin lymphoma (NHL). Verastem Oncology’s duvelisib was selected for the LLS’s Therapy Acceleration Program® (TAP) which provides additional resources to support the development of therapies for patients with blood cancers.

  • Business Wirelast month

    Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a poster presentation of preclinical data by Jonathan Pachter, Ph.D., the Company’s Chief Scientific Officer, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C. “We have assessed the activity of duvelisib, our orally-administered dual inhibitor of PI3K-delta and PI3K-gamma, in combination with either immune checkpoint or co-stimulatory antibodies in syngeneic antitumor models,” said Dr. Pachter. “Results to be presented at SITC’s 33rd Annual Meeting demonstrated that duvelisib shows strong anti-tumor synergy with PD-1 or OX40 antibodies.

  • Business Wirelast month

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its common stock to one new employee and 40,000 restricted stock units (RSUs) to another new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.18 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on November 1, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

  • ACCESSWIRElast month

    Cannabis and Biotech Firms Making Investors Boatloads

    HENDERSON, NV / ACCESSWIRE / November 1, 2018 / With so many opportunities at excellent entry points we decided highlighting one of the more interesting companies on the market, Endonovo Therapeutics, Inc. (ENDV). There are several other diseases the Sofpulse might help with including counteracting the effects of nonalcoholic steatohepatitis (NASH). In a pre-clinical study, one to 2 weeks of treatment with Sofpulse®, the non-invasive proprietary device of Endonovo Therapeutics, appeared to counteract several of the disease signs associated with NASH-associated liver damage.

  • Business Wirelast month

    Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting

    − Clinical Study Evaluating the Use of Duvelisib in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma to be Highlighted in an Oral Presentation −

  • What's in Store for Verastem (VSTM) This Earnings Season?
    Zacks2 months ago

    What's in Store for Verastem (VSTM) This Earnings Season?

    On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Verastem Oncology Announces Executive Leadership Appointments and Changes

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.’s Chief Financial Officer Gina Consylman to its Board of Directors. Ms. Consylman, who will also serve as the Chair of the Board’s Audit Committee, replaces Louise Phanstiel who is leaving the Board to pursue other professional opportunities.

  • ACCESSWIRE2 months ago

    A Stock to be "Aware of" for Liver Cancer Awareness Month

    HENDERSON, NV / ACCESSWIRE / October 18, 2018 / October is Liver Cancer Awareness month. According to the American Cancer Society, liver cancer incidence has more than tripled since 1980, liver cancer death rates have increased by almost 3% per year since 2000 and more than 700,000 people are diagnosed with liver cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year.

  • Here's Why Verastem Dropped Precipitously Today
    Motley Fool2 months ago

    Here's Why Verastem Dropped Precipitously Today

    Convertible notes issued by the biotech will dilute investors.

  • Business Wire2 months ago

    Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes

    Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the pricing of an offering of 5.00% Convertible Senior Notes due 2048 (the Convertible Notes) through a registered direct offering. The aggregate principal amount of Convertible Notes to be sold in the offering is $150 million. The Convertible Notes will be unsecured, will bear interest at a rate of 5.00% per annum, paid semi-annually in arrears, and will mature on November 1, 2048, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date.

  • ACCESSWIRE2 months ago

    Cannabis and Biotech Stocks That Are Set to Explode!

    HENDERSON, NV / ACCESSWIRE / October 11, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...

  • Business Wire2 months ago

    National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® added COPIKTRA™ capsules to the Clinical Practice Guidelines in Oncology for chronic lymphocytic leukemia/small lymphocytic lymphoma .

  • GuruFocus.com2 months ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week from the following companies: Barings BDC and Verastem

  • Business Wire2 months ago

    National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology

    Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® added COPIKTRA™ capsules to the Clinical Practice Guidelines in Oncology for follicular lymphoma .

  • Business Wire2 months ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 193,980 shares of Verastem Oncology's common stock and 50,000 restricted stock units (RSUs) to one new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire2 months ago

    Verastem Oncology Announces Publication of the Phase 3 DUO Study Results in the Journal Blood

    Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the results of the Phase 3 DUO™ study, which evaluated COPIKTRA™ capsules versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma , was published online in the peer-reviewed journal Blood.

  • ACCESSWIRE2 months ago

    These Stocks Are on The Brink of Breakouts

    While it may be a little late on VSTM, there is another company working on a solution to the same cancers that has made impressive progress recently and could be the next major success story in the sector, Propanc Biopharma, Inc. (PPCB). PPCB is an intriguing biotech firm, that erupted for over 7000% last month going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain as of the close on Wednesday. PPCB may start receiving increased attention from the street at any moment.

  • TheStreet.com3 months ago

    Verastem Could Be Purchased After a Test of the 200-Day Average Line

    Buyer beware this is a risky investment. In this daily bar chart of VSTM, below, we can see that prices have made an impressive rally from early April as prices moved from just $3 to briefly over $10. Prices are still above the rising 200-day line.